Tert-butyl (S)-1-(3-(1H-pyrazol-4-yl)phenylamino)-1-oxo-3-phenylpropan-2-ylcarbamate | 1240522-92-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Tert-butyl (S)-1-(3-(1H-pyrazol-4-yl)phenylamino)-1-oxo-3-phenylpropan-2-ylcarbamate
• 英文别名: tert-butyl N-[(2S)-1-oxo-3-phenyl-1-[3-(1H-pyrazol-4-yl)anilino]propan-2-yl]carbamate
• CAS: 1240522-92-2
• 化学式: C₂₃H₂₆N₄O₃
• 分子量: 406.484
• InChiKey: IDQFIBXVFJADDS-FQEVSTJZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  96.1
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Tert-butyl (S)-1-(3-(1H-pyrazol-4-yl)phenylamino)-1-oxo-3-phenylpropan-2-ylcarbamate 在 三乙酰氧基硼氢化钠 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 (2S)-N-(3-(1H-pyrazol-4-yl)phenyl)-3-phenyl-2-(thiazol-4-ylmethylamino)propanamide
  参考文献：
  名称：

  Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus

  摘要：

  The discovery and initial optimization of a series of phenylalanine based agonists for GPR142 is described. The structure-activity-relationship around the major areas of the molecule was explored to give agonists 90 times more potent than the initial HTS hit in a human GPR142 inositol phosphate accumulation assay. Removal of CYP inhibition by exploration of the pyridine A-ring is also described. (C) 2012 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2012.07.063
• 作为产物：
  描述：

  (S)-tert-butyl 1-(3-bromophenylamino)-1-oxo-3-phenylpropan-2-ylcarbamate 、 4-吡唑硼酸频哪醇酯 以to give tert-butyl (S)-1-(3-(1H-pyrazol-4-yl)phenylamino)-1-oxo-3-phenylpropan-2-ylcarbamate 33.C的产率得到Tert-butyl (S)-1-(3-(1H-pyrazol-4-yl)phenylamino)-1-oxo-3-phenylpropan-2-ylcarbamate
  参考文献：
  名称：

  Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions

  摘要：

  本文提供的是I式化合物，其中A、B、X、R1、R2和下标n的定义如下所述。还提供了包含这些化合物的组合物，以及它们的使用方法，例如用于治疗2型糖尿病和2型糖尿病相关疾病。

  公开号：

  US08785468B2

文献信息

• PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS
  申请人：Du Xiaohui

  公开号：US20120115811A1

  公开（公告）日：2012-05-10

  Provided herein are compounds of formula I: wherein A, B, X, R 1 , R 2 and subscript n are as defined in the following disclosure. Compositions comprising the compounds are also provided, as well as methods for their use, for example, in treatment of type 2 diabetes and type 2 diabetes-related conditions.

  本文所提供的是I式化合物：其中A、B、X、R1、R2和下标n如下所述。本文还提供了包含该化合物的组合物，以及使用它们的方法，例如用于治疗2型糖尿病和2型糖尿病相关疾病的方法。
• US8785468B2
  申请人：——

  公开号：US8785468B2

  公开（公告）日：2014-07-22
• [EN] PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS<br/>[FR] DÉRIVÉS DE LA PHÉNYLALANINE-AMIDE UTILES POUR LE TRAITEMENT DE MALADIES ET ÉTATS LIÉS À L'INSULINE
  申请人：AMGEN INC

  公开号：WO2010093849A2

  公开（公告）日：2010-08-19

  Provided herein are compounds of formula I: wherein A, B, X, R1, R2 and subscript n are as defined in the following disclosure. Compositions comprising the compounds are also provided, as well as methods for their use, for example, in treatment of type 2 diabetes and type 2 diabetes-related conditions.
• Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus
  作者：Mike Lizarzaburu、Simon Turcotte、Xiaohui Du、Jason Duquette、Angela Fu、Jonathan Houze、Leping Li、Jinqian Liu、Michiko Murakoshi、Kozo Oda、Ryo Okuyama、Futoshi Nara、Jeff Reagan、Ming Yu、Julio C. Medina

  DOI：10.1016/j.bmcl.2012.07.063

  日期：2012.9

  The discovery and initial optimization of a series of phenylalanine based agonists for GPR142 is described. The structure-activity-relationship around the major areas of the molecule was explored to give agonists 90 times more potent than the initial HTS hit in a human GPR142 inositol phosphate accumulation assay. Removal of CYP inhibition by exploration of the pyridine A-ring is also described. (C) 2012 Published by Elsevier Ltd.
• Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
  申请人：Du Xiaohui

  公开号：US08785468B2

  公开（公告）日：2014-07-22

  Provided herein are compounds of formula I: wherein A, B, X, R1, R2 and subscript n are as defined in the following disclosure. Compositions comprising the compounds are also provided, as well as methods for their use, for example, in treatment of type 2 diabetes and type 2 diabetes-related conditions.

  本文提供的是I式化合物，其中A、B、X、R1、R2和下标n的定义如下所述。还提供了包含这些化合物的组合物，以及它们的使用方法，例如用于治疗2型糖尿病和2型糖尿病相关疾病。